内科理论与实践

内科理论与实践 >

2024 , Vol. 19 >Issue 05: 333 - 336

DOI: https://doi.org/10.16138/j.1673-6087.2024.05.09

综述

凝血因子XIII与静脉血栓栓塞症研究进展

  • 谢学猛 ,
  • 胡玲
展开
  • 1.济宁医学院附属医院重症医学科，山东 济宁 272007
    2.济宁医学院临床医学院，山东 济宁 272067
胡玲 E-mail：3504534595@qq.com

收稿日期: 2024-02-05

  网络出版日期: 2025-01-16

基金资助

济宁市重点研发计划项目(2023YXNS114)

收起

Research progress of coagulation factor XIII and venous thromboembolism

  • XIE Xuemeng ,
  • HU Ling
Expand
  • 1. Department of Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China
    2. Clinical Medicine College, Jining Medical University, Jining 272067, China

Received date: 2024-02-05

  Online published: 2025-01-16

Fold

摘要

静脉血栓栓塞症（venous thromboembolism, VTE）是世界范围内第三大常见心血管疾病，其发病率仍然呈上升趋势。凝血因子XIII（factor XIII，FXIII）又称纤维蛋白稳定因子，参与凝血级联反应的多个环节。近来研究发现FXIII是决定静脉血栓体积、结构和稳定性的关键因子，可能在深静脉血栓的形成、脱落或溶解过程中扮演重要角色。本文就此展开综述，以期为VTE的预防、诊断和治疗提供新思路。

关键词： 静脉血栓栓塞症; 深静脉血栓形成; 肺栓塞; 凝血因子XIII

本文引用格式

谢学猛 , 胡玲 . 凝血因子XIII与静脉血栓栓塞症研究进展[J]. 内科理论与实践, 2024 , 19(05) : 333 -336 . DOI: 10.16138/j.1673-6087.2024.05.09

Abstract

Venous thromboembolism (VTE) is the third most common cardiovascular disease worldwide, and its incidence continues to rise. Coagulation factor XIII (FXIII, factor XIII), also known as fibrin stabilization factor, is involved in multiple stages of the clotting cascade. Recent studies have found that FXIII is a key factor in determining the volume, structure and stability of venous thrombosis, and may play an important role in the formation, shedding or dissolution of deep venous thrombosis. This paper reviews the research progress of FXIII and VTE, in order to provide new ideas for the prevention, diagnosis and treatment of VTE.

Key words： Venous thromboembolism; Deep vein thrombosis; Pulmonary embolism; Coagulation factor XIII

参考文献

[1] Khan F, Tritschler T, Kahn SR, et al. Venous thromboembolism[J]. Lancet, 2021, 398(10294):64-77.
[2] Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism[J]. Nat Rev Cardiol, 2023, 20(4):248-262.
[3] Law Y, Chan YC, Cheng SWK. Epidemiological updates of venous thromboembolism in a Chinese population[J]. Asian J Surg, 2018, 41(2):176-182.
[4] Javed H, Singh S, Ramaraje Urs SU, et al. Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beyond[J]. Blood Rev, 2023, 59:101032.
[5] Al-Horani RA, Kar S. Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism[J]. Eur J Med Chem, 2020, 200:112442.
[6] Chernysh IN, Nagaswami C, Kosolapova S, et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli[J]. Sci Rep, 2020, 10(1):5112.
[7] Mitchell JL, Little G, Bye AP, et al. Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability[J]. Res Pract Thromb Haemost, 2023, 7(5):100200.
[8] Kattula S, Byrnes JR, Martin SM, et al. Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice[J]. Blood Adv, 2018, 2(1):25-35.
[9] Duval C, Baranauskas A, Feller T, et al. Elimination of fibrin γ-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi[J]. Proc Natl Acad Sci U S A, 2021, 118(27):e2103226118.
[10] Kattula S, Sang Y, de Ridder G, et al. Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk[J]. J Thromb Haemost, 2021, 19(12):2997-3007.
[11] Shaya SA, Gani DM, Weitz JI, et al. Factor XIII prevents pulmonary emboli in mice by stabilizing deep vein thrombi[J]. Thromb Haemost, 2019, 119(6):992-999.
[12] Z?bczyk M, Natorska J, Undas A. Factor XIII and fibrin clot properties in acute venous thromboembolism[J]. Int J Mol Sci, 2021, 22(4):1607.
[13] Kool RO, Kohler HP, Coutinho JM, et al. Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis[J]. Thromb Res, 2017, 159:96-99.
[14] Tang N, Sun Z, Li D, et al. Combined measurement of factor XIII and D-dimer is helpful for differential diagnosis in patients with suspected pulmonary embolism[J]. Clin Chem Lab Med, 2017, 55(12):1948-1953.
[15] Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness[J]. Thromb Haemost, 2003, 90(3):434-438.
[16] Broni? A, Feren?ak G, Bernat R, et al. Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease[J]. J Med Biochem, 2021, 40(2):138-149.
[17] Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease[J]. J Thromb Haemost, 2023, 21(11):3005-3015.
[18] Wolberg AS, Sang Y. Fibrinogen and factor XIII in venous thrombosis and thrombus stability[J]. Arterioscler Thromb Vasc Biol, 2022, 42(8):931-941.
[19] Muszbek L, Bagoly Z, Bereczky Z, et al. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis[J]. Cardiovasc Hematol Agents Med Chem, 2008, 6(3):190-205.
[20] Mei?ner L, Schürmann P, D?rk T, et al. Genetic association study of fatal pulmonary embolism[J]. Int J Legal Med, 2021, 135(1):143-151.
[21] Kupis RW, Goldman-Mazur S, Polak M, et al. Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism[J]. Sci Rep, 2019, 9(1):72.
[22] Sawai Y, Yamanaka Y, Nomura S. Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients[J]. Vasc Health Risk Manag, 2020, 16:103-110.
[23] Weeks KS, Herbach E, McDonald M, et al. Meta-analysis of VTE risk: ovarian cancer patients by stage, histology, cytoreduction, and ascites at diagnosis[J]. Obstet Gynecol Int, 2020, 2020:2374716.
[24] Zeerleder S, Schroeder V, L?mmle B, et al. Factor XIII in severe sepsis and septic shock[J]. Thromb Res, 2007, 119(3):311-318.
[25] Al-Nasser B. Influence of tobacco smoking on perioperative risk of venous thromboembolism[J]. Turk J Anaesthesiol Reanim, 2020, 48(1):11-16.
[26] Rijken DC, Abdul S, Malfliet JJ, et al. Compaction of fibrin clots reveals the antifibrinolytic effect of factor[J]. J Thromb Haemost, 2016, 14(7):1453-1461.
[27] Hur WS, Warner H, Machan L, et al. Coagulation factor XIII-A and activated FXIII-A decrease in some deep vein thrombosis patients following catheter-directed thrombolysis[J]. Blood Coagul Fibrinolysis, 2019, 30(4):176-180.
[28] Liu Y, Crossen J, Stalker TJ, et al. Fluorescent peptide for detecting factor XIIIa activity and fibrin in whole blood clots forming under flow[J]. Res Pract Thromb Haemost, 2023, 8(1):102291.
[29] Wang Y, Xu X, Zhao X, et al. Functionalized polymeric hybrid micelles as an efficient nanotheranostic agent for thrombus imaging and thrombolysis[J]. Acta Biomater, 2021, 122:278-290.
[30] Andrews JPM, Portal C, Walton T, et al. Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer[J]. Eur Heart J Cardiovasc Imaging, 2020, 21(6):673-682.
[31] Daneshpour N, Collighan R, Perrie Y, et al. Indwelling catheters and medical implants with FXIIIa inhibitors: a novel approach to the treatment of catheter and medical device-related infections[J]. Eur J Pharm Biopharm, 2013, 83(1):106-113.
[32] Macor P, Durigutto P, Argenziano M, et al. Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein Ⅰ as a novel thrombus-specific thrombolytic strategy[J]. Haematologica, 2023, 108(7):1861-1872.
[33] Marin E, Kornilov DA, Bukhdruker SS, et al. Structural insights into thrombolytic activity of destabilase from medicinal leech[J]. Sci Rep, 2023, 13(1):6641.
[34] Quintal Martínez JP, Segura Campos MR. Bioactive compounds and functional foods as coadjuvant therapy for thrombosis[J]. Food Funct, 2023, 14(2):653-674.
Options
文章导航

/

〈 〉